Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Regeneron Pharmaceuticals, Inc. (REGN:NASDAQ), powered by AI.

Current Price
$761.85
Sector
Healthcare
What is the Regeneron Pharmaceuticals, Inc. stock price forecast?

Regeneron Pharmaceuticals, Inc. is currently trading at $761.85. View real-time AI analysis on Alpha Lenz.

What is Regeneron Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Regeneron Pharmaceuticals, Inc. on Alpha Lenz.

What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?

View Regeneron Pharmaceuticals, Inc.'s valuation metrics on Alpha Lenz.

Regeneron Pharmaceuticals, Inc.

$761.85
NASDAQREGN
Ask about Regeneron Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

Regeneron Pharmaceuticals, Inc.'s ROE is 14.9%. Explore profitability and growth together.

Ask for details

Company Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative medicines that address serious medical conditions. The company is recognized for its robust research platforms, particularly in the fields of immunology, oncology, and rare diseases. By leveraging advanced genetic and molecular technologies, Regeneron develops therapies targeting a broad spectrum of diseases worldwide, including ophthalmic, cardiovascular, and infectious conditions. Its portfolio includes several blockbuster biologic drugs, further underscoring its scientific leadership in monoclonal antibodies and gene therapy. Regeneron plays a pivotal role in the global healthcare sector, providing treatments that improve patient outcomes and collaborating with external partners to advance new therapeutic options. The company’s strong financial performance, with substantial revenues and consistent profitability, highlights its significant presence and influence within the biotech industry, driving both medical innovation and market growth.

CEODr. Leonard S. Schleifer M.D., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees15,182

Company Statistics

(FY 2025)

Profile

Market CapN/A
Revenue$14.34B
Shares Out0.00
Employees15,182

Margins

Gross85.35%
EBITDA34.83%
Operating25.81%
Pre-Tax36.47%
Net31.41%

Valuation

P/EN/A
P/BN/A
EV/SalesN/A
EV/EBITDAN/A
P/FCFN/A

Growth (CAGR)

Rev 3Yr5.62%
Rev 5Yr11.04%
Op Inc 3Yr-9.50%
Op Inc 5Yr0.69%
Net Inc 3Yr1.26%
Net Inc 5Yr5.10%

Returns

ROA11.50%
ROE14.87%
ROIC13.47%

Financial Health

Cash & Cash Equivalents$3.12B
Net Debt$6.18B
Debt/Equity29.76%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Regeneron Pharmaceuticals, Inc. (Healthcare) Stock Forecast & Analysis $761.85 | Alpha Lenz